Coeptis Therapeutics Holdings Inc
COEP14.660USD
+0.020+0.14%
收盤 12/19, 16:00（美東）報價延遲15分鐘
75.61M總市值
虧損本益比TTM
關於 Coeptis Therapeutics Holdings Inc 公司
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Coeptis Therapeutics Holdings Inc簡介
公司代碼COEP
公司名稱Coeptis Therapeutics Holdings Inc
上市日期Dec 17, 2020
CEOMehalick (David)
員工數量5
證券類型Ordinary Share
年結日Dec 17
公司地址105 Bradford Road, Suite 420
城市WEXFORD
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編15090
電話17249346467
網址https://coeptistx.com/
公司代碼COEP
上市日期Dec 17, 2020
CEOMehalick (David)
Coeptis Therapeutics Holdings Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
-100.00%
名稱
名稱/職務
職務
持股
持股變動
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月20日 週四
更新時間: 11月20日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Calise (Chris)
5.86%
Mehalick (David)
2.44%
Armistice Capital LLC
1.77%
The Vanguard Group, Inc.
0.95%
Sheehy (Christine Elise)
0.95%
其他
88.04%
持股股東
持股股東
佔比
Calise (Chris)
5.86%
Mehalick (David)
2.44%
Armistice Capital LLC
1.77%
The Vanguard Group, Inc.
0.95%
Sheehy (Christine Elise)
0.95%
其他
88.04%
股東類型
持股股東
佔比
Individual Investor
10.17%
Hedge Fund
2.12%
Investment Advisor/Hedge Fund
1.22%
Investment Advisor
1.18%
其他
85.31%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
36
241.64K
3.38%
--
2025Q3
37
241.64K
3.76%
+42.71K
2025Q2
35
198.94K
3.83%
+46.67K
2025Q1
35
152.27K
2.68%
+61.98K
2024Q4
37
107.84K
11.51%
-74.49K
2024Q3
50
182.34K
16.17%
+98.47K
2024Q2
52
83.87K
26.32%
-153.34K
2024Q1
74
237.20K
33.65%
-370.03K
2023Q4
75
236.65K
31.22%
+72.09K
2023Q3
78
164.55K
39.28%
-2.06K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Calise (Chris)
312.69K
6.49%
--
--
Sep 11, 2025
Mehalick (David)
130.07K
2.7%
--
--
Sep 11, 2025
Armistice Capital LLC
94.77K
1.97%
+94.77K
--
Sep 30, 2024
The Vanguard Group, Inc.
27.53K
0.57%
+3.09K
+12.65%
Jun 30, 2025
Sheehy (Christine Elise)
50.53K
1.05%
--
--
Sep 11, 2025
Yerace (Daniel Alexander)
45.53K
0.94%
-5.00K
-9.89%
Sep 11, 2025
Geode Capital Management, L.L.C.
20.28K
0.42%
+311.00
+1.56%
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
公告日期
類型
比率
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
常見問題
Coeptis Therapeutics Holdings Inc的前五大股東是誰？
Coeptis Therapeutics Holdings Inc的前五大股東如下：
Calise (Chris)持有股份：312.69K佔總股份比例：6.49%。
Mehalick (David)持有股份：130.07K佔總股份比例：2.70%。
Armistice Capital LLC持有股份：94.77K佔總股份比例：1.97%。
The Vanguard Group, Inc.持有股份：27.53K佔總股份比例：0.57%。
Sheehy (Christine Elise)持有股份：50.53K佔總股份比例：1.05%。
Calise (Chris)持有股份：312.69K佔總股份比例：6.49%。
Mehalick (David)持有股份：130.07K佔總股份比例：2.70%。
Armistice Capital LLC持有股份：94.77K佔總股份比例：1.97%。
The Vanguard Group, Inc.持有股份：27.53K佔總股份比例：0.57%。
Sheehy (Christine Elise)持有股份：50.53K佔總股份比例：1.05%。
Coeptis Therapeutics Holdings Inc的前三大股東類型是什麼？
Coeptis Therapeutics Holdings Inc 的前三大股東類型分別是：
Calise (Chris)
Mehalick (David)
Armistice Capital LLC
Calise (Chris)
Mehalick (David)
Armistice Capital LLC
有多少機構持有Coeptis Therapeutics Holdings Inc(COEP)的股份？
截至2025Q4，共有36家機構持有Coeptis Therapeutics Holdings Inc的股份，合計持有的股份價值約為241.64K，占公司總股份的3.38% 。與2025Q3相比，機構持股有所增加，增幅為-0.38%。
哪個業務部門對Coeptis Therapeutics Holdings Inc的收入貢獻最大？
在--，--業務部門對Coeptis Therapeutics Holdings Inc的收入貢獻最大，創收--，占總收入的--% 。
